Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma. - Andreikos DA; Argyropoulou I; Theocharopoulos C; Anastasopoulou A; Stefanou D; Lyrarakis G; Schadendorf D; Gogas H; Ziogas DC (Targeted oncology, 2026)